Mirum was founded in 2018.
Mirum is incorporated in the state of Delaware.
950 Tower Lane, Suite 1050, Foster City, CA 94404.
You can view our board of directors by visiting the “Board of Directors” section of our website.
You can view our management team by visiting the “Management Team” section of our website.
Mirum’s fiscal year ends December 31.
Ernst & Young LLP.
Mirum is traded on the Nasdaq Global Market under the symbol “MIRM”.
Mirum went public in July 2019.
As Mirum trades publicly on the NASDAQ, shares can be purchased through a stockbroker of your choice.
Mirum does not currently offer a direct stock purchase plan.
Currently, Mirum does not offer a dividend or a dividend reinvestment program.
Mirum’s CUSIP number is 604749 101.
Mirum’s transfer agent is the American Stock Transfer and Trust Company (AST). You can find more information about how to contact American Stock Transfer at: https://www.astfinancial.com/contact-us.
Please contact our transfer agent at: https://www.astfinancial.com/contact-us. AST can look up your records and make any necessary adjustments. There is a fee involved for replacing lost certificates.
Quarterly & Annual Reports and other investor materials, when available, can be found in “Financial Information” in the “Investor Relations” section of our corporate website. Additionally, all SEC filings can be accessed directly from the SEC at www.sec.gov.
You can view our recent press releases by visiting the “News Releases” section of our website.
For media inquiries please send an email to media@mirumpharma.com.
You can view more information on our development programs by visiting the “Our Medicines” section of our website.
For investor related questions please send an email to ir@mirumpharma.com.
Please visit the “Email Alerts” section of our website and fill out our web-form to be added to our distribution list.
You can reach Investor Relations by calling (650) 667-4085 or sending an email to ir@mirumpharma.com.